Hoffmann-la Roche

This study tests a new medicine called crovalimab against the current standard, eculizumab, in about 190 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are already on similar treatments. The goal is to see if crovalimab is safer and works as well or better. Participant…

This study tests an experimental drug called cevostamab in people with multiple myeloma that has returned or not responded to other treatments. About 90 participants who have already tried a type of BCMA-targeted therapy will receive the drug through an IV. The goal is to see if …

This study tests two new drug combinations for people with advanced kidney cancer that hasn't been treated before. About 199 participants will receive either a standard treatment or one of two experimental combos to see if they are safer and work better. The goal is to control th…

This study tests whether adding two immunotherapy drugs (atezolizumab and tiragolumab) after standard chemoradiation can help eliminate rectal cancer in people with locally advanced disease. About 58 adults with resectable rectal cancer will receive either the drug combination or…

This study tests a new medicine called zifibancimig for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The treatment is given as an eye injection or through a small implant that releases the drug over time. The goal is to see if it is saf…

This study tests whether fenebrutinib can reduce brain lesions in people with relapsing multiple sclerosis (RMS). About 109 participants received either the drug or a placebo, and brain scans were taken over 12 weeks. The goal is to see if fenebrutinib slows disease activity, wit…

This study tests whether adding obinutuzumab to standard treatment helps people with lupus-related kidney disease (lupus nephritis) achieve better kidney function. About 271 adults with active kidney inflammation took part. The goal was to see if the drug could improve kidney res…

This study offers continued treatment with atezolizumab (a cancer immunotherapy) to patients who were already receiving it in a previous Roche-sponsored trial. It includes about 382 adults with various cancers. The goal is to keep providing the drug and monitor long-term safety a…

This study tests a gene therapy (delandistrogene moxeparvovec) in children under 4 with Duchenne muscular dystrophy, a severe muscle-weakening disease. The goal is to see if the treatment is safe and helps produce a key muscle protein. About 13 children will take part and be foll…

This study follows about 1,000 Chinese adults with diffuse large B-cell lymphoma (a type of blood cancer) to see how well the drug polatuzumab works in everyday medical practice. Researchers will measure how long the cancer stays under control and track side effects. The study in…

This study tests an experimental drug called RO7795081, taken once daily for 38 weeks, to help adults with obesity or overweight who also have weight-related health problems (like high blood pressure or sleep apnea) lose weight. About 352 participants will receive either the drug…

This study tests whether a higher dose of the drug ocrelizumab can better slow disability progression in people with relapsing multiple sclerosis (MS) compared to the standard dose. About 864 adults with MS will receive either the higher or approved dose every 24 weeks. The main …

This early-stage study tests the safety of an experimental drug called RO7669330, given as an eye injection, for people with geographic atrophy (a severe form of dry age-related macular degeneration). The study involves 27 participants and will monitor side effects and eye health…

This study looks at how a medicine called emicizumab affects joint health, physical activity, and overall well-being in people aged 13 to 69 with moderate or severe hemophilia A. Participants receive emicizumab as a preventive treatment. The goal is to see if it reduces joint pro…

This study tests a new medicine, crovalimab, in 83 adults and teens with a rare disease called atypical hemolytic uremic syndrome (aHUS). The goal is to see if crovalimab can control the disease by preventing damage to small blood vessels and kidneys. Participants receive crovali…

This study looks at whether adding the targeted drug alectinib to standard chemotherapy is safe for people with a certain type of lung cancer (ALK-positive non-small cell lung cancer) after they have had surgery to remove the tumor. The trial involves 11 participants with stage I…

This study compares two medications, ocrelizumab and fingolimod, in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see which drug better reduces the number of MS relapses and new brain lesions. Participants will receive one of th…

This study tests an experimental drug called RO7204239 in 51 adults with facioscapulohumeral muscular dystrophy (FSHD), a condition that causes progressive muscle weakness. The drug is an antibody designed to block a protein that may contribute to muscle wasting. Participants rec…

This study tests whether a new drug, fenebrutinib, is better than an existing medication (teriflunomide) at reducing relapses and slowing disability in people with relapsing multiple sclerosis. About 746 adults with MS will be randomly assigned to one of the two treatments. The m…

This study offers continued access to the cancer drug atezolizumab for people who were already benefiting from it in a previous Roche-sponsored trial. It includes 49 participants who need ongoing treatment and do not have local access to the drug. The main goal is to provide unin…

This phase 3 study tests whether adding lurbinectedin to atezolizumab as maintenance therapy helps people with extensive-stage small-cell lung cancer live longer without their cancer growing. Participants must have stable disease or better after initial chemotherapy plus atezoliz…

This study tests whether the drug atezolizumab can prevent bladder cancer from coming back after surgery to remove the bladder. It includes 761 people with high-risk muscle-invasive bladder cancer who had their bladder removed and still have cancer DNA in their blood. Participant…

This early-stage study tests a new drug, RO7567132, alone or with another drug (atezolizumab) in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and how the drug moves through the body. About 34 participant…

This study tests an experimental drug called obinutuzumab in 303 people with active lupus. The drug targets immune cells to reduce disease flares. Participants receive either the drug or a placebo, plus their usual treatments. The main goal is to see if more people achieve a sign…

This study tests whether adding a new drug called inavolisib to two standard treatments (palbociclib and fulvestrant) can help people with a certain type of advanced breast cancer live longer without their disease getting worse. The cancer must have a specific gene change (PIK3CA…

This study tests a medicine called emicizumab in 55 babies from birth to 12 months old with severe hemophilia A. The medicine is given as a shot under the skin every 2 weeks for a year, then less often for up to 7 more years. The goal is to see if it safely reduces the number of …

This study tests the safety and dosing of ocrelizumab in 23 children and teens (ages 10–18) with relapsing-remitting multiple sclerosis over 2 years. The goal is to find the right dose for a future larger study. Participants must have a diagnosis of RRMS and stable symptoms befor…

This study offers ongoing access to the cancer drug atezolizumab for patients who were already benefiting from it in earlier Roche-sponsored trials. It includes up to 1,000 participants and focuses on safety and continued treatment. The goal is to provide uninterrupted therapy fo…

This study tests an oral medicine called risdiplam in infants up to 6 weeks old who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The goal is to see if early treatment helps them reach motor milestones like sitting without support. 26 infants took…

This study tests whether adding a new drug called tiragolumab to two existing drugs (atezolizumab and bevacizumab) can help control advanced liver cancer better than the two-drug combo alone. About 687 adults with untreated, advanced liver cancer that cannot be removed by surgery…

This study tests whether adding the drug giredestrant to standard treatment (Phesgo) can help people with a certain type of advanced breast cancer (HER2-positive, ER-positive) live longer without their cancer growing. About 922 participants who have not had prior treatment for ad…

This study tests a new medicine called crovalimab against an existing one, eculizumab, in people with a rare blood disease called paroxysmal nocturnal hemoglobinuria (PNH) who haven't had complement inhibitor therapy before. The goal is to see if crovalimab is as good as eculizum…

This study compares a new drug, fenebrutinib, with an approved medication (teriflunomide) in about 750 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take one of the two pil…

This study looks at how well the drug ocrelizumab works and how safe it is over 4 years in people with progressive multiple sclerosis (MS). About 927 participants will receive the treatment to see if it can slow down disability, reduce relapses, and control brain lesions. The goa…

This study offers ongoing treatment with alectinib or crizotinib to people with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. About 200 participants will continue their medication while doctors monitor for side effects and saf…

This study tests a new drug combination (inavolisib plus fulvestrant) against an existing one (alpelisib plus fulvestrant) in people with a specific type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation) that has worsened after prior treatment. About …

This study tests whether adding an experimental drug (RO7204239) to an existing weight-loss medication (tirzepatide) helps people with obesity or overweight lose more weight over 48 weeks. About 285 adults without diabetes will participate. The goal is to see if the combination i…

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can improve outcomes for people with HER2-positive stomach or gastroesophageal junction cancer that can be surgically removed. About 42 participants wi…

This early-stage study tests whether the drug RO7204239 can improve how the body uses insulin in people with type 2 diabetes who are also overweight or obese. About 30 participants will receive either the drug or a placebo for 24 weeks. The main goal is to measure changes in insu…

This study tests a new drug, giredestrant, combined with palbociclib against a standard treatment (letrozole plus palbociclib) for people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 992 participants will receive either the new combination or t…

This study tests several treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are chosen based on specific genetic markers (biomarkers) in their tumors. The goal is to see if these targeted therapies can delay cancer grow…

This study tests a drug called crovalimab in 41 children with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and kidney damage. The goal is to see if the drug can control the disease and improve kidney function. Participants receive crovalimab…

This study tests two new drug combinations (tobemstomig alone or with tiragolumab) against a standard drug (atezolizumab) in people with advanced bladder cancer who cannot receive platinum chemotherapy. The goal is to see if these combinations are safer and work better. About 204…

This study tests whether a new drug called glofitamab, when added to chemotherapy, works better than the current standard treatment for people with diffuse large B-cell lymphoma that has returned or stopped responding to prior therapy. About 270 adults will be randomly assigned t…

This study tests whether adding tiragolumab to atezolizumab can help prevent esophageal cancer from returning after standard chemoradiation. About 760 people with inoperable esophageal squamous cell carcinoma will receive either the drug combination, atezolizumab alone, or placeb…

This study tests an experimental drug called tominersen in people with early-stage Huntington's disease. About 300 participants will receive either the drug or a placebo to see if it is safe and can slow the disease. The goal is to reduce harmful proteins in the brain and preserv…

This study tests a drug called satralizumab for people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging, pain, and double vision. About 131 adults will receive either the drug or a placebo to see if it reduces eye bulging by at least 2 millimeters …

This study tests an experimental drug called entrectinib in children and teens with advanced solid tumors or brain tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors, especially in those with specific gene…

This study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging, double vision, and pain. The main goal is to see if the drug reduces eye bulging by at least 2 millimeters after 24 weeks. Participants rece…

This study tests whether ocrelizumab (Ocrevus) can slow disability worsening in adults with primary progressive multiple sclerosis (PPMS), including those with more advanced disease. About 1,000 participants receive either the drug or a placebo, and researchers measure changes in…

This study tests a new drug called glofitamab, which helps the immune system attack cancer cells. It is for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to other treatments. The study aims to find the best dose and check if the drug is safe and ef…

This study tests whether adding the immunotherapy drug atezolizumab to the targeted therapy trastuzumab emtansine (T-DM1) can prevent breast cancer from returning in people with HER2-positive breast cancer who still have cancer cells after initial treatment and surgery. About 1,1…

This study tests whether the immunotherapy drug atezolizumab can help prevent lung cancer from returning in people with stage IB to IIIA non-small cell lung cancer who have already had surgery and chemotherapy. About 1,280 participants will receive either atezolizumab for 16 cycl…

This study tests a new drug called tobemstomig combined with chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this combination works better than the current standard treatment (pembrolizumab plus chemo) at slo…

This study tests a new drug called giredestrant against standard hormone therapies in over 4,000 people with early-stage, hormone-sensitive breast cancer. The goal is to see if giredestrant is better at stopping the cancer from coming back. Participants take the drug daily for se…

This study tests several targeted therapies for people with advanced or metastatic non-small cell lung cancer. A simple blood test identifies specific genetic changes in the cancer, allowing doctors to match patients with drugs that may shrink tumors or slow disease progression. …

This study tests a new medicine called faricimab against an existing treatment (ranibizumab) for people with vision loss caused by abnormal blood vessels in the eye due to severe nearsightedness. About 280 participants will receive injections as needed after an initial dose. The …

This study tests whether a higher dose of ocrelizumab can better slow disability progression in adults with primary progressive multiple sclerosis (PPMS). About 769 participants receive either the approved dose or a higher dose every 24 weeks. The main goal is to see if the highe…

This study tests a new drug called ZN-A-1041, taken as a capsule, for people with advanced HER2-positive solid tumors (cancers that have spread). The drug is given alone or with other standard cancer medicines. The main goals are to check safety, find the best dose, and see if it…

This study aimed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in people with antiphospholipid syndrome (APS). APS is an autoimmune condition that raises the risk of clots. The trial was planned for adults aged 18–70 with at least tw…

This study tests a new medicine called Afimkibart (RO7790121) for people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. About 400 adults who haven't responded well to other treatments will receive either the drug or a plac…

This study compares a new daily oral medication, fenebrutinib, with the standard infusion ocrelizumab in 985 adults with primary progressive multiple sclerosis (PPMS). The goal is to see which treatment better delays worsening disability. Participants receive either fenebrutinib …

This early-stage study tests a new medicine called RO7790121 in 50 adults with advanced liver scarring (fibrosis) caused by MASH. The main goal is to check the drug's safety and how the body processes it. Participants must have a certain body mass index and liver stiffness level.…

This study tests a new drug called RO7790121 in about 21 adults with moderate to severe Crohn's disease who haven't responded well to standard treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and stomach pain. Participants …

This study tests a new medicine, Afimkibart, for people with moderate to severe eczema (atopic dermatitis). About 160 adults will receive either the drug or a placebo to see if it improves skin symptoms like redness and itching. The main goal is to measure at least a 75% improvem…

This study follows about 1,300 people with multiple sclerosis who are already taking ocrelizumab to see how safe and effective it is over the long term. Participants continue their treatment and are checked for side effects, disability changes, and brain lesion activity. The goal…

This study tests whether adding the immunotherapy drug atezolizumab to standard targeted therapies (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. The trial includes 557 adults whose cancer worsened after initial treatment with atezolizumab and beva…

This study tests whether a refillable eye implant (Port Delivery System) filled with the drug ranibizumab can be safely refilled every 36 weeks instead of every 24 weeks for people with wet age-related macular degeneration. About 451 participants who have already responded to sta…

This study gives ongoing access to the cancer drug pertuzumab for people with solid tumors who were already benefiting from it in a previous Roche study. About 154 participants will continue treatment until their disease gets worse or side effects become too severe. The goal is t…

This study tests whether adding the drug glofitamab to a standard chemotherapy regimen (Pola-R-CHP) can better control large B-cell lymphoma in people who have not yet been treated. About 1,130 participants will receive either the new combination or the standard treatment alone. …

This study tests whether taking alectinib pills for two years after lung cancer surgery works better than standard chemotherapy to prevent the cancer from returning. It includes 257 adults with a specific type of lung cancer called ALK-positive, at stages IB to IIIA. Participants…

This study aimed to test whether adding the drug inavolisib to standard chemotherapy and bevacizumab could help people with a specific genetic form of advanced colorectal cancer (PIK3CA-mutated). It was designed for people who had not yet received treatment for their metastatic c…

This study tests a combination of two drugs, mosunetuzumab and lenalidomide, in people with follicular lymphoma, a type of blood cancer. The goal is to see if the combination is safe and effective, and to compare giving one drug as a shot under the skin versus through a vein. Abo…

This study tests a new two-drug combination (mosunetuzumab plus lenalidomide) against a standard combination (rituximab plus lenalidomide) in people with follicular lymphoma whose cancer returned after at least one prior treatment. The goal is to see if the new combo delays cance…

This study tests whether adding an experimental drug (RO7204239) that helps muscles grow to an existing SMA treatment (risdiplam) can improve motor function more than risdiplam alone. About 259 people with SMA, aged 2 to 25 years, will take part. The goal is to see if the combina…

This study tests several new drugs chosen based on the unique markers of each person's rare ovarian cancer. It includes 176 adults whose cancer has persisted or returned after standard treatment. The goal is to see if these targeted therapies can shrink tumors or slow the disease…

This study tests a new drug called divarasib against two existing drugs (sotorasib and adagrasib) for people with a specific type of advanced lung cancer (KRAS G12C-positive non-small cell lung cancer). About 338 participants who have already tried other treatments will be random…

This study tested a newer targeted drug, alectinib, against an older one, crizotinib, in 187 Asian patients with a specific type of advanced lung cancer (ALK-positive). The goal was to see which drug better delays cancer growth. Patients took pills twice daily. Results help docto…

This study tests an experimental daily pill (RO7269162) in 256 people who are at risk for or have very early Alzheimer's disease. Participants either have brain plaques but no symptoms, or mild cognitive impairment. The trial checks safety and whether the drug reduces amyloid pla…

This study tests a new drug, englumafusp alfa, combined with other treatments (obinutuzumab and glofitamab) in about 500 adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior therapy. The goal is to see if the combination is safe and can shrink…

This study tests a new drug, crovalimab, in about 50 people aged 12 and older with PNH, a rare blood disorder that destroys red blood cells. Participants have not received similar treatments before. The goal is to see if crovalimab can control the breakdown of red blood cells and…

This study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a high-risk type of lymphoma (DLBCL) who have not been treated before. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 …

This study tests a new drug called giredestrant against standard hormone therapies for people with a common type of advanced breast cancer (ER+/HER2-). About 300 participants who have already tried one or two prior treatments will be randomly assigned to receive either giredestra…

This study tests a drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking these faulty genes. About 534 adults with various cancers, including lung, breast, and br…

This study tests whether adding tiragolumab to standard atezolizumab plus chemotherapy helps people with untreated extensive-stage small cell lung cancer live longer without their cancer growing. About 123 adults in China are participating. The goal is to see if the new combinati…

This study tests an experimental drug called prasinezumab in people with early Parkinson's disease. The drug is designed to target and remove clumps of a protein thought to play a role in Parkinson's. 316 participants will receive either the drug or a placebo for 52 weeks, with a…

This study tests whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who have had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence will receive either the drug combination …

This study tests the drug atezolizumab in 60 people with advanced non-small cell lung cancer whose tumors have high levels of a protein called PD-L1 and who have not had chemotherapy before. The goal is to see if the drug helps them live longer and slows cancer growth. Participan…

This study tests an experimental drug called RO7126209 in 241 people with early to moderate Alzheimer's disease. The goal is to see if the drug is safe and how it affects amyloid plaques in the brain. Participants receive multiple doses of the drug or a placebo through an IV.

This study tests whether giving cancer drugs based on the unique genetic changes in a person's tumor can shrink or control advanced solid tumors. About 920 adults and children with cancers that have spread or cannot be removed will receive a treatment chosen specifically for thei…

This study tests a daily pill called giredestrant in 30 people with Grade 1 endometrial cancer (a low-grade uterine cancer). The goal is to see if the drug can shrink or stop the cancer from growing over 6 months, possibly avoiding or delaying surgery. Participants take the drug …

This study tests whether a combination of two drugs (mosunetuzumab and polatuzumab vedotin) works better than standard chemotherapy for people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. About 208 adults with certain types of lymphoma will…

This study tests whether adding the targeted drug polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the current standard (R-CHOP) for people with untreated diffuse large B-cell lymphoma. About 1000 participants will receive either the new combination or the s…

This study tests a new once-daily medicine called RO7795081 to see if it helps lower blood sugar in adults with type 2 diabetes. About 240 participants will take the study drug, a placebo (inactive pill), or an approved diabetes medicine (semaglutide) for 30 weeks. The main goal …

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer procedure called TACE works better than TACE alone. About 342 adults with liver cancer that hasn't spread outside the liver and who are at high risk of poor results f…

This study tests a new treatment called OpRegen, made from human stem cells, for people with advanced dry age-related macular degeneration (geographic atrophy). The cells are injected under the retina to replace damaged support cells. The main goal is to check safety, but researc…

This study tests a new drug called tobemstomig combined with chemotherapy for people with a hard-to-treat breast cancer that has spread. About 83 participants will get either the new combo or a standard treatment. The goal is to see if the new combo helps keep cancer from growing…

This study tests a combination of three drugs (glofitamab, atezolizumab or polatuzumab vedotin, plus a pre-treatment of obinutuzumab) in adults with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. The goal is to find the safest dose and see if…

This study tests a drug called obinutuzumab against a standard treatment (tacrolimus) in 142 adults with primary membranous nephropathy, a kidney disease that spills protein into urine. The goal is to see if obinutuzumab can bring the disease into complete remission by week 104, …

This study tests a drug called obinutuzumab against a standard treatment (MMF) in children and young adults with a kidney condition that causes frequent relapses. The goal is to see if obinutuzumab can keep the disease in remission longer and reduce the need for steroids. About 8…

This study tests a medicine called faricimab, given as an eye injection, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if injections every 24 weeks (about twice a year) can safely maintain or improve vision. About …

This study tests a drug called satralizumab in 30 children (ages 8 to 17) with Duchenne muscular dystrophy who are already taking steroids. The goal is to see if the drug can improve bone density and is safe. The study is active but not recruiting new participants.

This study tests an experimental drug called prasinezumab in people with early Parkinson's disease who are already on standard medication. The goal is to see if the drug can delay worsening of movement problems. About 586 participants will receive either the drug or a placebo by …

This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will r…

This study follows over 2,700 patients with bladder, lung, or liver cancer who received the drug atezolizumab as part of their normal care. Researchers are tracking how long patients live and how well the drug controls the cancer outside of strict clinical trial settings. The goa…

This study observes how doctors manage and treat people with ALK-positive advanced non-small cell lung cancer who are taking the drug alectinib in everyday practice. Researchers will track outcomes like how long the cancer stays under control and overall survival. The study does …

This study is observing 6,000 adults already receiving Roche eye treatments for conditions like wet macular degeneration and diabetic eye swelling. It does not test new drugs or change standard care. Instead, it collects long-term data on vision changes, treatment patterns, and s…

This study looks at how well certain biological markers (biomarkers) work to track dry eye disease and how they change with standard treatments like Vevye® or Xiidra®. About 378 people with moderate to severe dry eye and healthy volunteers will take part. The goal is to better un…

This study follows 1,200 people in China newly diagnosed with advanced non-small-cell lung cancer (stage IIIB/IIIC/IV) that cannot be removed by surgery. Researchers will collect information from medical records and follow patients over time to see what treatments doctors use, ho…